DUBLIN–(BUSINESS WIRE)–The “Investigation Report on China’s Rituximab Market 2021-2025” report has been added to ResearchAndMarkets.com’s providing.
In response to this market analysis, the gross sales income of Rituximab within the Chinese language market in 2016-2019 has an rising pattern.
Rituximab is a monoclonal antibody to focus on cells which have the CD20 marker on their floor. It’s primarily used to deal with ailments attributable to extreme B lymphocytes, together with lymphoma, persistent lymphocytic leukemia, transplantation rejection, and sure autoimmune ailments. The unique drug was developed by Roche. Rituximab was launched in China in 2000. In 2020, moreover Roche and its subsidiary company, Genentech, one other important producer within the Chinese language market is Shanghai Henlius.
The gross sales income of Rituximab in China will increase from CNY943 million in 2016 to CNY1.42 billion in 2019. The gross sales worth of Rituximab in China was roughly CNY1.3 billion in 2020. It decreased 8.4% 12 months on 12 months. The rationale for the gross sales decline is that the COVID-19 epidemic has impacted the hospitals’ general operation. The CAGR of the gross sales worth of Rituximab in China is 8.4% from 2016 to 2020.
The analyst analyzes that because the epidemic scenario has been improved and the hospitals resume their operation, gross sales of Rituximab may have a restoration development from 2021 to 2025. As well as, gross sales will even improve because of the market growth. In comparison with indications permitted in some developed international locations, Rituximab has fewer indications being permitted in China. The one two permitted indications are non-Hodgkin’s lymphoma and persistent lymphocytic leukemia.
Thus, the opportunity of the elevated variety of indications might carry new goal sufferers for Rituximab. Moreover, with the emergence of biosimilar medication, Roche was not the monopoly within the Chinese language Rituximab market. Consequently, the value of Rituximab will likely be extra reasonably priced sooner or later, which can result in a rise in gross sales quantity.
- The affect of COVID-19 on China’s Rituximab market
- Gross sales worth and quantity of China’s Rituximab 2016-2020
- Aggressive panorama of China’s Rituximab market
- Costs of Rituximab in China
- Costs of Rituximab in China by areas and producers
- Evaluation of things affecting the event of China’s Rituximab market
- Prospect of China’s Rituximab market from 2021 to 2025
Key Matters Lined:
1 Related Ideas of Rituximab
1.1 Indications for Rituximab
1.2 Growth of Rituximab in China
1.3 Governmental Approval of Rituximab in China
1.4 The Influence of COVID-19 on Rituximab gross sales in China
2 Gross sales of Rituximab in China, 2016-2020
2.1 Gross sales Worth of Rituximab
2.1.1 Total Gross sales Worth
2.1.2 Gross sales Worth by Area
2.2 Gross sales Quantity of Rituximab
2.2.1 Total Gross sales Quantity
2.2.2 Gross sales Quantity by Area
2.3 Gross sales of Rituximab by Dosage Type in China, 2016-2020
2.3.2 Evaluation of Different Dosage Types
3 Evaluation of Main Rituximab Producers in China, 2016-2020
3.1 Evaluation of Market Share of Main Rituximab Producers
3.1.1 Investigation on Market Share by Gross sales Worth
3.1.2 Investigation on Market Share by Gross sales quantity
3.2 Roche Pharma (Schweiz) AG
3.2.1 Enterprise Profile
3.2.2 Gross sales of MabThera (Roche’s Rituximab) in China
3.3 Shanghai Henlius Biotech, Inc.
3.3.1 Enterprise Profile
3.3.2 Gross sales of Hanlikang (Henlius’s Rituximab) in China
3.4 Genentech Inc
3.4.1 Enterprise Profile
3.4.2 Gross sales of RITUXAN (Genentech’s Rituximab) in China
4 Costs of Rituximab for Completely different Producers in China, 2020-2021
4.1 Roche Pharma (Schweiz) AG (MabThera)
4.2 Shanghai Henlius Biotech, Inc. (Hanlikang)
4.3 Genentech Inc (RITUXAN)
5 Prospect of Chinese language Rituximab drug Market, 2021-2025
5.1 Influential Components of Chinese language Rituximab Market Growth
5.1.1 The Influence of COVID-19 on Chinese language Rituximab Market
5.1.2 Market Drivers and Alternatives
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Measurement
5.3 Forecast on Market Development
For extra details about this report go to https://www.researchandmarkets.com/r/ljviu0